Retrospective survival analysis of 237 consecutive patients with multiple pulmonary metastases from advanced renal cell carcinoma exclusively resected by a 1318-nm laser

Baier, Barbara; Kern, Alexander; Kaderali, Lars; Bis, B; Koschel, Dirk; Rolle, Axel

doi:10.1093/icvts/ivv120

Cited by 18 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other point of this study is that only laser resection allows complete removal of multiple and centrally located metastases in a tissue-saving way, and this is confirmed by other recent reports. 21,22 Our results show that laser resection of lung metastases can achieve good results in terms of radical resection and survival, as a conventional surgical metastasectomy limiting damage to the lung. Stapler resection of a high number of metastases would mutilate the lung.…”

Section: Discussionmentioning

confidence: 72%

Pulmonary Laser Metastasectomy by 1318-nm Neodymium-Doped Yttrium-Aluminum Garnet Laser: A Retrospective Study About Laser Metastasectomy of the Lung

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 72%

Pulmonary Laser Metastasectomy by 1318-nm Neodymium-Doped Yttrium-Aluminum Garnet Laser: A Retrospective Study About Laser Metastasectomy of the Lung

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Finally, Baier and colleagues examined complete resection of multi-focal pulmonary RCC metastases (mean 13/patient). Using laser resection in 237 patients, they achieved complete resection in 208 for a median OS of 69 months compared with 19 months for those with an incomplete resection (p < 0.00001) [14]. Although a higher number of metastases was associated with a shorter OS, the advantage of complete resection was maintained for all levels of disease.…”

Section: Lungmentioning

confidence: 98%

Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review

Achkar

Maranchie

Appleman

2019

KCA

View full text Add to dashboard Cite

Introduction: Metastasectomy for advanced renal cell carcinoma has been practiced for over 80 years. However, there is uncertainty regarding the clinical benefit of this procedure and the optimum selection of appropriate patients. Materials and Methods: A systematic literature search was conducted according to the PRISMA statement to identify studies that reported outcomes in patients who underwent metastasectomy at any time. Primary endpoints were overall and disease-free survival. Radiation therapy studies were not included. Case reports and series with less than 20 patients were not included. Results: Forty-four studies were identified that met the criteria for inclusion, with a total of 4195 patients. No studies that randomized patients to surgery versus no surgery were identified. Disease-free interval, number of metastatic sites and completeness of resection were prognostic for overall survival in many of the included studies. Seventeen studies included patients with lung metastases only (1465 patients in total). Conclusions: Case series have documented patients with prolonged disease-free interval and survival after metastasectomy. However, without randomized data, the impact of metastasectomy on outcomes in patients with metastatic renal cell carcinoma (mRCC) remains unknown, especially in the evolving landscape of systemic therapies.

show abstract

“…Publications focused on sarcomatous metastases gather studies mostly emphasizing hard tissue sarcomas (54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)(68), others mostly soft tissue sarcomas (69)(70)(71)(72)(73)(74)(75)(76) and the residual mostly other sarcomas (77)(78)(79)(80)(81)(82)(83)(84)(85)(86)(87)(88)(89). The remaining studies mentioned lung metastases from primary tumors other than colorectal cancers and sarcomas (90)(91)(92)(93)(94)(95)(96)(97)(98)(99)(100)(101)(102)…”

Section: Redo Pulmonary Metastasectomy In Specific Settingsmentioning

confidence: 99%

“…Twenty papers in total dealt with lung metastases from primary tumors other than colorectal cancers and sarcomas (90)(91)(92)(93)(94)(95)(96)(97)(98)(99)(100)(101)(102)(103)(104)(105)(106)(107)(108)(109). In view of the small number of studies for each different primary, we deemed more appropriate to present them comprehensively as an "other tumors" group.…”

Section: Reports Focused On Tumors Other Than Colorectal and Sarcomamentioning

confidence: 99%

Results of redo pulmonary metastasectomy

2021

View full text Add to dashboard Cite

Repeat surgical resection (redo) for pulmonary metastases is a questionable, albeit intriguing topic. We performed an extensive review of the literature, to specifically analyze results of redo pulmonary metastasectomies. We reviewed a total of 3,523 papers. Among these, 2,019 were excluded for redundancy and 1,105 because they were not completely retrievable. Out of 399 eligible papers, 183 had missing information or missing abstract, while 96 lacked data on survival. A total of 120 papers dated from 1991 onwards were finally included. Data regarding mortality, major morbidity, prognostic factors and long-term survivals of the first redo pulmonary metastasectomies were retrieved and analyzed. Homogeneity of data was affected by the lack of guidelines for redo pulmonary metastasectomy and the risks of bias when comparing different studies has to be considered. According to the histology sub-types, redo metastasectomies papers were grouped as: colorectal (n=42), sarcomas (n=36), others (n=20) and all histologies (n=22); the total number of patients was 3,015. Data about chemotherapy were reported in half of the papers, whereas targeted or immunotherapy in 9. None of these associated therapies, except chemotherapy in two records, did significantly modify outcomes. Disease-free interval before the redo procedure was the prevailing prognostic factor and nearly all papers showed a significant correlation between patients' comorbidities and prognosis. No perioperative mortality was reported, while perioperative major morbidity was overall quite low. Where available, overall survival after the first redo metastasectomy ranged from 10 to 72 months, with a 5-years survival of approximately 50%. The site of first recurrence after the redo procedure was mainly lung. Despite the data retrievable from literature are heterogeneous and confounding, we can state that redo lung metastasectomy is worthwhile when the lesions are resectable and the perioperative risk is low. At present, there are no "non-surgical" therapeutic options to replace redo pulmonary metastasectomies.

show abstract

Retrospective survival analysis of 237 consecutive patients with multiple pulmonary metastases from advanced renal cell carcinoma exclusively resected by a 1318-nm laser

Abstract: If complete resection is achieved, laser resection can remove even high numbers of metastases with considerable and comparable long-term survival known from previous reports. This tissue-saving technique allows repeated resections in case of recurrence.

Cited by 18 publications

References 23 publications

Pulmonary Laser Metastasectomy by 1318-nm Neodymium-Doped Yttrium-Aluminum Garnet Laser: A Retrospective Study About Laser Metastasectomy of the Lung

Pulmonary Laser Metastasectomy by 1318-nm Neodymium-Doped Yttrium-Aluminum Garnet Laser: A Retrospective Study About Laser Metastasectomy of the Lung

Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review

Results of redo pulmonary metastasectomy

Contact Info

Product

Resources

About